\begin{thebibliography}{}

\bibitem[Ankerst et~al., 2015]{ankerst2015precision}
Ankerst, D.~P., Xia, J., Thompson~Jr, I.~M., Hoefler, J., Newcomb, L.~F.,
  Brooks, J.~D., Carroll, P.~R., Ellis, W.~J., Gleave, M.~E., Lance, R.~S.,
  et~al. (2015).
\newblock Precision medicine in active surveillance for prostate cancer:
  development of the canary--early detection research network active
  surveillance biopsy risk calculator.
\newblock {\em European Urology}, 68(6):1083--1088.

\bibitem[Balasubramanian and Lagakos, 2003]{balasubramanian2003estimation}
Balasubramanian, R. and Lagakos, S.~W. (2003).
\newblock Estimation of a failure time distribution based on imperfect
  diagnostic tests.
\newblock {\em Biometrika}, 90(1):171--182.

\bibitem[Bokhorst et~al., 2015]{bokhorst2015compliance}
Bokhorst, L.~P., Alberts, A.~R., Rannikko, A., Valdagni, R., Pickles, T.,
  Kakehi, Y., Bangma, C.~H., Roobol, M.~J., and {\relax {PRIAS} study group}
  (2015).
\newblock Compliance rates with the {Prostate Cancer Research International
  Active Surveillance ({PRIAS})} protocol and disease reclassification in
  noncompliers.
\newblock {\em European Urology}, 68(5):814--821.

\bibitem[Bratt et~al., 2013]{bratt2013study}
Bratt, O., Carlsson, S., Holmberg, E., Holmberg, L., Johansson, E., Josefsson,
  A., Nilsson, A., Nyberg, M., Robinsson, D., Sandberg, J., et~al. (2013).
\newblock The study of active monitoring in {Sweden (SAMS)}: a randomized study
  comparing two different follow-up schedules for active surveillance of
  low-risk prostate cancer.
\newblock {\em Scandinavian Journal of Urology}, 47(5):347--355.

\bibitem[Briganti et~al., 2018]{briganti2018active}
Briganti, A., Fossati, N., Catto, J.~W., Cornford, P., Montorsi, F., Mottet,
  N., Wirth, M., and Van~Poppel, H. (2018).
\newblock Active surveillance for low-risk prostate cancer: the {European
  Association of Urology} position in 2018.
\newblock {\em European Urology}, 74(3):357--368.

\bibitem[Bruinsma et~al., 2017]{bruinsma2017expert}
Bruinsma, S.~M., Roobol, M.~J., Carroll, P.~R., Klotz, L., Pickles, T., Moore,
  C.~M., Gnanapragasam, V.~J., Villers, A., Rannikko, A., Valdagni, R., et~al.
  (2017).
\newblock Expert consensus document: semantics in active surveillance for men
  with localized prostate cancerâ€”results of a modified {Delphi} consensus
  procedure.
\newblock {\em Nature Reviews Urology}, 14(5):312.

\bibitem[Bruinsma et~al., 2018]{gap3_2018}
Bruinsma, S.~M., Zhang, L., Roobol, M.~J., Bangma, C.~H., Steyerberg, E.~W.,
  Nieboer, D., Van~Hemelrijck, M., consortium, M. F. G. A. P. P. C. A. S.~G.,
  Trock, B., Ehdaie, B., et~al. (2018).
\newblock The {Movember} foundation's {GAP3} cohort: a profile of the largest
  global prostate cancer active surveillance database to date.
\newblock {\em BJU International}, 121(5):737--744.

\bibitem[Bul et~al., 2013]{bul2013active}
Bul, M., Zhu, X., Valdagni, R., Pickles, T., Kakehi, Y., Rannikko, A.,
  Bjartell, A., Van Der~Schoot, D.~K., Cornel, E.~B., Conti, G.~N., et~al.
  (2013).
\newblock Active surveillance for low-risk prostate cancer worldwide: the
  {PRIAS} study.
\newblock {\em European Urology}, 63(4):597--603.

\bibitem[Chesnut et~al., 2020]{chesnut2019role}
Chesnut, G.~T., Vertosick, E.~A., Benfante, N., Sjoberg, D.~D., Fainberg, J.,
  Lee, T., Eastham, J., Laudone, V., Scardino, P., Touijer, K., et~al. (2020).
\newblock Role of changes in magnetic resonance imaging or clinical stage in
  evaluation of disease progression for men with prostate cancer on active
  surveillance.
\newblock {\em European Urology}, 77(4):501--507.

\bibitem[Coley et~al., 2017]{coley2017prediction}
Coley, R.~Y., Zeger, S.~L., Mamawala, M., Pienta, K.~J., and Carter, H.~B.
  (2017).
\newblock Prediction of the pathologic {Gleason} score to inform a personalized
  management program for prostate cancer.
\newblock {\em European Urology}, 72(1):135--141.

\bibitem[Cooperberg et~al., 2018]{cooperberg2018refined}
Cooperberg, M.~R., Brooks, J.~D., Faino, A.~V., Newcomb, L.~F., Kearns, J.~T.,
  Carroll, P.~R., Dash, A., Etzioni, R., Fabrizio, M.~D., Gleave, M.~E., et~al.
  (2018).
\newblock Refined analysis of prostate-specific antigen kinetics to predict
  prostate cancer active surveillance outcomes.
\newblock {\em European Urology}, 74(2):211--217.

\bibitem[De~Boor, 1978]{de1978practical}
De~Boor, C. (1978).
\newblock {\em A practical guide to splines}, volume~27.
\newblock Springer-Verlag New York.

\bibitem[de~Carvalho et~al., 2017a]{de2017estimating}
de~Carvalho, T.~M., Heijnsdijk, E.~A., and de~Koning, H.~J. (2017a).
\newblock Estimating the risks and benefits of active surveillance protocols
  for prostate cancer: a microsimulation study.
\newblock {\em BJU International}, 119(4):560--566.

\bibitem[de~Carvalho et~al., 2017b]{carvalho2017}
de~Carvalho, T.~M., Heijnsdijk, E.~A., and de~Koning, H.~J. (2017b).
\newblock When should active surveillance for prostate cancer stop if no
  progression is detected?
\newblock {\em The Prostate}, 77(9):962--969.

\bibitem[Eilers and Marx, 1996]{eilers1996flexible}
Eilers, P.~H. and Marx, B.~D. (1996).
\newblock Flexible smoothing with {B-splines} and penalties.
\newblock {\em Statistical Science}, 11(2):89--121.

\bibitem[Epstein et~al., 2016]{epsteinGG2014}
Epstein, J.~I., Egevad, L., Amin, M.~B., Delahunt, B., Srigley, J.~R., and
  Humphrey, P.~A. (2016).
\newblock The 2014 international society of urological pathology ({ISUP})
  consensus conference on {Gleason} grading of prostatic carcinoma.
\newblock {\em The American Journal of Surgical Pathology}, 40(2):244--252.

\bibitem[Inoue et~al., 2018]{inoue2018comparative}
Inoue, L.~Y., Lin, D.~W., Newcomb, L.~F., Leonardson, A.~S., Ankerst, D.,
  Gulati, R., Carter, H.~B., Trock, B.~J., Carroll, P.~R., Cooperberg, M.~R.,
  et~al. (2018).
\newblock Comparative analysis of biopsy upgrading in four prostate cancer
  active surveillance cohorts.
\newblock {\em Annals of Internal Medicine}, 168(1):1--9.

\bibitem[Kasivisvanathan et~al., 2020]{kasivisvanathan2020magnetic}
Kasivisvanathan, V., Giganti, F., Emberton, M., and Moore, C.~M. (2020).
\newblock Magnetic resonance imaging should be used in the active surveillance
  of patients with localised prostate cancer.
\newblock {\em European Urology}, 77(3):318--319.

\bibitem[Laird et~al., 1982]{laird1982random}
Laird, N.~M., Ware, J.~H., et~al. (1982).
\newblock Random-effects models for longitudinal data.
\newblock {\em Biometrics}, 38(4):963--974.

\bibitem[Lin et~al., 2000]{lin2000latent}
Lin, H., McCulloch, C.~E., Turnbull, B.~W., Slate, E.~H., and Clark, L.~C.
  (2000).
\newblock A latent class mixed model for analysing biomarker trajectories with
  irregularly scheduled observations.
\newblock {\em Statistics in Medicine}, 19(10):1303--1318.

\bibitem[Loeb et~al., 2014]{loeb2014heterogeneity}
Loeb, S., Carter, H.~B., Schwartz, M., Fagerlin, A., Braithwaite, R.~S., and
  Lepor, H. (2014).
\newblock Heterogeneity in active surveillance protocols worldwide.
\newblock {\em Reviews in Urology}, 16(4):202--203.

\bibitem[Loeb et~al., 2013]{loeb2013systematic}
Loeb, S., Vellekoop, A., Ahmed, H.~U., Catto, J., Emberton, M., Nam, R.,
  Rosario, D.~J., Scattoni, V., and Lotan, Y. (2013).
\newblock Systematic review of complications of prostate biopsy.
\newblock {\em European Urology}, 64(6):876--892.

\bibitem[Makarov et~al., 2007]{makarov2007updated}
Makarov, D.~V., Trock, B.~J., Humphreys, E.~B., Mangold, L.~A., Walsh, P.~C.,
  Epstein, J.~I., and Partin, A.~W. (2007).
\newblock Updated nomogram to predict pathologic stage of prostate cancer given
  prostate-specific antigen level, clinical stage, and biopsy {Gleason} score
  ({Partin} tables) based on cases from 2000 to 2005.
\newblock {\em Urology}, 69(6):1095--1101.

\bibitem[Mottet et~al., 2017]{mottet2017eau}
Mottet, N., Bellmunt, J., Bolla, M., Briers, E., Cumberbatch, M.~G., De~Santis,
  M., Fossati, N., Gross, T., Henry, A.~M., Joniau, S., et~al. (2017).
\newblock Eau-estro-siog guidelines on prostate cancer. part 1: screening,
  diagnosis, and local treatment with curative intent.
\newblock {\em European Urology}, 71(4):618--629.

\bibitem[Nieboer et~al., 2018]{nieboer2018active}
Nieboer, D., Tomer, A., Rizopoulos, D., Roobol, M.~J., and Steyerberg, E.~W.
  (2018).
\newblock Active surveillance: a review of risk-based, dynamic monitoring.
\newblock {\em Translational Andrology and Urology}, 7(1):106--115.

\bibitem[Nixon et~al., 1997]{nixon1997biological}
Nixon, R.~G., Wener, M.~H., Smith, K.~M., Parson, R.~E., Strobel, S.~A., and
  Brawer, M.~K. (1997).
\newblock Biological variation of prostate specific antigen levels in serum: an
  evaluation of day-to-day physiological fluctuations in a well-defined cohort
  of 24 patients.
\newblock {\em The Journal of Urology}, 157(6):2183--2190.

\bibitem[Partin et~al., 1993]{partin1993use}
Partin, A.~W., Yoo, J., Carter, H.~B., Pearson, J.~D., Chan, D.~W., Epstein,
  J.~I., and Walsh, P.~C. (1993).
\newblock The use of prostate specific antigen, clinical stage and {Gleason}
  score to predict pathological stage in men with localized prostate cancer.
\newblock {\em The Journal of Urology}, 150(1):110--114.

\bibitem[Pearson et~al., 1994]{pearson1994mixed}
Pearson, J.~D., Morrell, C.~H., Landis, P.~K., Carter, H.~B., and Brant, L.~J.
  (1994).
\newblock Mixed-effects regression models for studying the natural history of
  prostate disease.
\newblock {\em Statistics in Medicine}, 13(5-7):587--601.

\bibitem[Rizopoulos, 2012]{rizopoulos2012joint}
Rizopoulos, D. (2012).
\newblock {\em Joint Models for Longitudinal and Time-to-Event Data: With
  Applications in R}.
\newblock CRC Press.

\bibitem[Rizopoulos, 2016]{rizopoulosJMbayes}
Rizopoulos, D. (2016).
\newblock The {R} package {JMbayes} for fitting joint models for longitudinal
  and time-to-event data using {MCMC}.
\newblock {\em Journal of Statistical Software}, 72(7):1--46.

\bibitem[Rizopoulos et~al., 2017]{rizopoulos2017dynamic}
Rizopoulos, D., Molenberghs, G., and Lesaffre, E.~M. (2017).
\newblock Dynamic predictions with time-dependent covariates in survival
  analysis using joint modeling and landmarking.
\newblock {\em Biometrical Journal}, 59(6):1261--1276.

\bibitem[Royston and Altman, 2013]{royston2013external}
Royston, P. and Altman, D.~G. (2013).
\newblock External validation of a cox prognostic model: principles and
  methods.
\newblock {\em BMC medical research methodology}, 13(1):33.

\bibitem[Schoots et~al., 2015]{schoots2015magnetic}
Schoots, I.~G., Petrides, N., Giganti, F., Bokhorst, L.~P., Rannikko, A.,
  Klotz, L., Villers, A., Hugosson, J., and Moore, C.~M. (2015).
\newblock Magnetic resonance imaging in active surveillance of prostate cancer:
  a systematic review.
\newblock {\em European Urology}, 67(4):627--636.

\bibitem[Steyerberg et~al., 2010]{steyerberg2010assessing}
Steyerberg, E.~W., Vickers, A.~J., Cook, N.~R., Gerds, T., Gonen, M.,
  Obuchowski, N., Pencina, M.~J., and Kattan, M.~W. (2010).
\newblock Assessing the performance of prediction models: a framework for some
  traditional and novel measures.
\newblock {\em Epidemiology (Cambridge, Mass.)}, 21(1):128.

\bibitem[Tomer et~al., 2019a]{tomer2019}
Tomer, A., Nieboer, D., Roobol, M.~J., Steyerberg, E.~W., and Rizopoulos, D.
  (2019a).
\newblock Personalized schedules for surveillance of low-risk prostate cancer
  patients.
\newblock {\em Biometrics}, 75(1):153--162.

\bibitem[Tomer et~al., 2019b]{tomer2019personalized}
Tomer, A., Rizopoulos, D., Nieboer, D., Drost, F.-J., Roobol, M.~J., and
  Steyerberg, E.~W. (2019b).
\newblock Personalized decision making for biopsies in prostate cancer active
  surveillance programs.
\newblock {\em Medical Decision Making}, 39(5):499--508.

\bibitem[Turnbull, 1976]{turnbull1976empirical}
Turnbull, B.~W. (1976).
\newblock The empirical distribution function with arbitrarily grouped,
  censored and truncated data.
\newblock {\em Journal of the Royal Statistical Society. Series B
  (Methodological)}, 38(3):290--295.

\end{thebibliography}
